No connection

Search Results

ITGR vs TXG

ITGR
Integer Holdings Corporation
NEUTRAL
Price
$84.64
Market Cap
$2.91B
Sector
Healthcare
AI Confidence
85%
TXG
10x Genomics, Inc.
NEUTRAL
Price
$22.97
Market Cap
$2.93B
Sector
Healthcare
AI Confidence
85%

Valuation

P/E Ratio
ITGR
29.29
TXG
--
Forward P/E
ITGR
11.71
TXG
114.85
P/B Ratio
ITGR
1.66
TXG
3.68
P/S Ratio
ITGR
1.57
TXG
4.56
EV/EBITDA
ITGR
11.17
TXG
-38.94

Profitability

Gross Margin
ITGR
27.39%
TXG
69.13%
Operating Margin
ITGR
12.79%
TXG
-9.42%
Profit Margin
ITGR
5.55%
TXG
-6.77%
ROE
ITGR
6.11%
TXG
-5.78%
ROA
ITGR
4.75%
TXG
-6.4%

Growth

Revenue Growth
ITGR
5.0%
TXG
0.6%
Earnings Growth
ITGR
52.9%
TXG
--

Financial Health

Debt/Equity
ITGR
0.75
TXG
0.11
Current Ratio
ITGR
3.32
TXG
4.46
Quick Ratio
ITGR
2.05
TXG
3.95

Dividends

Dividend Yield
ITGR
--
TXG
--
Payout Ratio
ITGR
0.0%
TXG
0.0%

AI Verdict

ITGR NEUTRAL

Integer Holdings (ITGR) presents a dichotomy between strong forward-looking earnings potential and weak current market sentiment. The Piotroski F-Score of 4/9 indicates stable but not robust financial health, while the stock is currently trading almost exactly at its growth-based intrinsic value of $85.26, leaving no margin of safety. While the trailing P/E is high, the Forward P/E of 11.71 and explosive YoY earnings growth of 52.9% suggest a significant valuation correction is underway. However, a bearish technical trend and negative insider sentiment temper the bullish analyst consensus.

Strengths
Exceptional short-term liquidity with a Current Ratio of 3.32
Strong earnings acceleration with 52.9% YoY growth
Attractive Forward P/E (11.71) compared to trailing P/E (29.29)
Risks
Lack of margin of safety as price ($84.64) equals intrinsic value ($85.26)
Stagnant revenue growth (5% YoY) suggesting earnings growth is driven by cost-cutting rather than expansion
Bearish technical trend (0/100) and negative insider sentiment
TXG NEUTRAL

TXG exhibits a stark divergence between its strong balance sheet liquidity and its poor operational health, evidenced by a weak Piotroski F-Score of 2/9. While the company maintains a very low Debt/Equity ratio (0.11) and a robust Current Ratio (4.46), revenue growth has stagnated at 0.60% YoY. The stock is currently trading at a significant premium with a Forward P/E of 114.85, despite negative profit margins. Recent price recovery is strong, but insider selling and bearish technical trends suggest caution.

Strengths
Exceptional liquidity with a Current Ratio of 4.46
Very low leverage (Debt/Equity of 0.11)
Strong Gross Margins at 69.13%
Risks
Stagnant revenue growth (0.60% YoY)
Poor financial trend indicated by Piotroski F-Score of 2/9
Extremely high valuation (Forward P/E 114.85)

Compare Another Pair

ITGR vs TXG: Head-to-Head Comparison

This page compares Integer Holdings Corporation (ITGR) and 10x Genomics, Inc. (TXG) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI Chat
Markets
Profile